Combination therapy with EGFR-TKIs (e.g., erlotinib) and anti-VEGFR (e.g., bevacizumab) agents has been shown to prolong PFS in patients with NSCLC in a few randomized controlled trials [11]. Here, KDR is linked to non-small cell lung carcinoma.